PDCD1 and metastatic melanoma: Since the approval of ipilimumab for the treatment of metastatic melanoma in 2010, cancer therapy with immune checkpoint inhibitors (ICIs) targeting either the cytotoxic T-lymphocyte antigen 4 (CTLA-4) or the programmed cell death protein 1 (PD-1) pathway has increased exponentially [1].